veracyte is a pioneering genomic diagnostics company. our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. we ask the right questions to resolve ambiguity and bring assurance to light, rendering tens of thousands of costly and unnecessary surgeries truly unnecessary. we are giving patients a clearer path forward. through scientific rigor we employ the best tools, best science and best minds to create tests that enable a more accurate diagnosis without the need for risky, costly and often unnecessary surgery. veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards. we are making a difference in the lives of physicians and patients. we are doing something real. .
Company profile
Ticker
VCYT
Exchange
Website
CEO
Bonnie Anderson
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CALDEROME INC
SEC CIK
Corporate docs
Subsidiaries
Veracyte International Corp. • Veracyte Global, B.V. • Veracyte SD, Inc. • Veracyte Labs SD Corporation • Veracyte Diagnostics, LLC • Veracyte SAS • Veracyte Labs VA Corporation • C2i Genomics Ltd ...
IRS number
205455398
VCYT stock data
Latest filings (excl ownership)
8-K/A
Consolidated Financial Statements
17 Apr 24
8-K
Other Events
22 Mar 24
424B7
Prospectus with selling stockholder info
22 Mar 24
8-K
Other Events
29 Feb 24
424B7
Prospectus with selling stockholder info
29 Feb 24
S-8
Registration of securities for employees
29 Feb 24
S-3ASR
Automatic shelf registration
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
22 Feb 24
8-K
Departure of Directors or Certain Officers
13 Feb 24
Transcripts
VCYT
Earnings call transcript
2023 Q4
22 Feb 24
VCYT
Earnings call transcript
2023 Q3
7 Nov 23
VCYT
Earnings call transcript
2023 Q2
8 Aug 23
VCYT
Earnings call transcript
2023 Q1
4 May 23
VCYT
Earnings call transcript
2022 Q4
23 Feb 23
VCYT
Earnings call transcript
2022 Q3
2 Nov 22
VCYT
Earnings call transcript
2022 Q2
3 Aug 22
VCYT
Earnings call transcript
2022 Q1
4 May 22
VCYT
Earnings call transcript
2021 Q4
1 Mar 22
VCYT
Earnings call transcript
2021 Q3
10 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 203.33 mm | 203.33 mm | 203.33 mm | 203.33 mm | 203.33 mm | 203.33 mm |
Cash burn (monthly) | (no burn) | (no burn) | 10.58 mm | 4.66 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 70.39 mm | 31.01 mm | n/a | n/a |
Cash remaining | n/a | n/a | 132.95 mm | 172.32 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | 12.6 | 37.0 | n/a | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 232 |
Opened positions | 29 |
Closed positions | 26 |
Increased positions | 95 |
Reduced positions | 76 |
13F shares | Current |
---|---|
Total value | 1.69 tn |
Total shares | 77.09 mm |
Total puts | 67.60 k |
Total calls | 150.80 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
ARK Investment Management | 7.59 mm | $169.56 bn |
Wellington Management | 7.07 mm | $157.83 bn |
Vanguard | 7.07 mm | $157.77 bn |
BLK Blackrock | 6.89 mm | $153.84 bn |
Artisan Partners Limited Partnership | 3.41 mm | $76.17 bn |
STT State Street | 3.25 mm | $72.60 bn |
Dimensional Fund Advisors | 3.21 mm | $71.72 bn |
CMTDF Sumitomo Mitsui Trust | 3.17 mm | $70.87 bn |
Nikko Asset Management Americas | 3.17 mm | $70.77 bn |
ArrowMark Colorado | 2.31 mm | $51.60 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Eastham Karin | Common Stock | Sell | Dispose S | No | Yes | 21.6528 | 10,000 | 216.53 k | 33,125 |
1 Apr 24 | Eastham Karin | Common Stock | Option exercise | Acquire M | No | Yes | 13.19 | 10,000 | 131.90 k | 43,125 |
1 Apr 24 | Eastham Karin | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 13.19 | 10,000 | 131.90 k | 0 |
15 Mar 24 | Rebecca Chambers | Common Stock | Payment of exercise | Dispose F | No | No | 21.1 | 2,189 | 46.19 k | 146,702 |
15 Mar 24 | Rebecca Chambers | Common Stock | Grant | Acquire A | No | No | 0 | 4,318 | 0.00 | 148,891 |
15 Mar 24 | Stapley Marc | Common Stock | Payment of exercise | Dispose F | No | No | 21.1 | 5,971 | 125.99 k | 329,740 |
15 Mar 24 | Stapley Marc | Common Stock | Grant | Acquire A | No | No | 0 | 11,780 | 0.00 | 335,711 |
6 Mar 24 | Stapley Marc | Common Stock | Grant | Acquire A | No | No | 0 | 114,724 | 0.00 | 323,931 |
6 Mar 24 | John Leite | Common Stock | Grant | Acquire A | No | No | 0 | 49,880 | 0.00 | 85,559 |
News
Veracyte Announces 9 Abstracts Reinforcing The Value Of Decipher Prostate And Decipher Bladder Testing Will Be Presented At AUA 2024
16 Apr 24
Goldman Sachs Maintains Buy on Veracyte, Lowers Price Target to $28
15 Apr 24
Cathie Wood's Ark Invest Dumps $17M In Coinbase Shares As The Exchange Grappled With Disruption Amid Bitcoin Rally
28 Feb 24
Cathie Wood's Ark Invest Sheds $9.3M Worth Of Coinbase Shares Amid Bitcoin Rally — Robinhood Stock Also Sold
27 Feb 24
Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed
26 Feb 24
Press releases
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
16 Apr 24
Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
27 Feb 24
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
22 Feb 24
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
21 Feb 24
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
8 Feb 24